Sentencing Delayed for Florida Retina Specialist Melgen

August 11, 2017: By Joan McKenna
Salomon Melgen

Salomon Melgen

A sentencing hearing for Florida retina specialist Salomon Melgen was postponed Aug. 10, a day before it was to set to start.

Melgen’s lawyers said in court documents filed Aug. 10 that all parties agreed to move the hearing to Dec. 4-6 due Melgen’s upcoming trial in New Jersey and the schedules of counsel.

Melgen’s joint trial on bribery charges with US Sen. Robert Menendez, D-NJ, is slated to begin Sept. 6.

In Florida, Melgen, 62, was convicted in April by a federal jury of 67 counts of Medicare fraud.

Melgen was accused of falsely diagnosing patients with macular degeneration and other retinal disorders, performing unnecessary procedures, and overcharging for Lucentis vials.

US prosecutors alleged that, between January 2008 and December 2013, Melgen billed Medicare for more than $190 million, for which he was reimbursed more than $105 million. The government said a substantial portion of these payments were obtained through fraudulent billing.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Bausch + Lomb Launches Stellaris Elite for Retinal Surgery in US

Sentencing Delayed for Florida Retina Specialist Melgen

Valeant Receives FDA Complete Response Letter for Vyzulta

US FDA Clears Optovue Software for Corneal Epithelial Thickness Mapping

Ocular Therapeutix Names Daniel Bollag as Regulatory Chief

Eylea Sales Continue to Increase; Lucentis Gains New Indications

RXi Pharmaceuticals Signs Common Stock Purchase Agreement for Up to $15 Million

Allegro’s Luminate Posts Positive Results in Phase IIb Stage 2 Trial for Diabetic Macular Edema

Omeros’ Omidria Revenues Grow 71 Percent

AGTC Receives US FDA Orphan Drug Designation for Gene Therapy to Treat X-Linked Retinitis Pigmentosa

Aerpio Shares Begin Trading on OTCQB Market

Aerie Reports FDA Concerns over Contract Manufacturer’s Plant

Valeant’s Bausch + Lomb Revenues Dip 3 percent in Q2-2017

Ocular Therapeutix Reports $66 Million in Cash, Cash Equivalents

Imprimis’ Q2-2017 Ophthalmology Revenues Increase 70 percent

Carl Zeiss Meditec’s Revenues Grow 7.5 Percent in Latest Quarter

Johnson & Johnson Vision to Acquire TearScience

Mynosys Receives $1 Million Grant from NEI to Commercialize Zepto

Ocular Therapeutix Eliminates 26 Positions; New CEO Takes Helm

Inotek Stops Development of Trabodenoson after Second Failed Study

Coming soon

2017 Glaucoma Pharmaceuticals Report: A Global Market Analysis for 2016 to 2022